Additional Information
Market: NYSE
Sector: Pharmaceuticals & Biotechnology
EPIC: IMUC
Latest Price: $1.20  (0,00%)
52-week High: $3.57
52-week Low: $0.72
Market Cap: $69.08M
1 year chart
Deal IMUC Tax Free*
*subject to change and depends on individual circumstances.
1 day chart
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
ImmunoCellular Therapeutics
www.imuc.com
Deal ImmunoCellular Therapeutics Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

ImmunoCellular Therapeutics, Ltd. is a development-stage company. The Company is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. The product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies...

Read more
Pdf

ImmunoCellular featured on CNN segment

August 15 2012, 4:29pm ImmunoCellular featured on CNN segment

ImmunoCellular Therapeutics (MKT:IMUC) announced Monday that it was featured on CNN’s Sanjay Gupta MD last weekend.

The show profiled the biotech company’s brain tumour vaccine ICT-107, which is in Phase 2b clinical trials to treat patients with glioblastoma multiforme, an aggressive brain cancer.

ImmunoCellular’s Phase 2 trial is a double-blind and placebo-controlled study aimed to evaluate the safety and efficacy of the vaccine.

The study is enrolling patients at medical institutions in collaboration with leading experts and opinion leaders in neuro-oncology.

Sanjay Gupta, a practicing neurosurgeon, reports on health and medical news for Starting Point with Soledad O’Brien, Anderson Cooper 360 and anchors the weekend medical affairs program during the weekends.

A transcript of the CNN show can be accessed, by clicking this link: http://edition.cnn.com/TRANSCRIPTS/1208/11/hcsg.01.html

In late July, the biotech company said the U.S. Food and Drug Administration gave clearance to start Phase I clinical trials of ICT-121, a vaccine that targets an antigen expressed in tumours. 

The trial, which will be performed at a Los Angeles-based medical centre, will test the vaccine on 20 patients with glioblastoma multiforme, an aggressive brain cancer.

Like ICT-107, now in Phase II trials treating subjects with the same type of brain cancer, the ICT-121 treatment is the second dendritic cell-based vaccine to enter the clinic.

Both brain tumour vaccines work by turning a patient’s immune system against tumour associated antigens. This is done by
pulling out dendritic cells and loading them with antigens. The cells, then, are reinserted into the patient’s body to trigger an immune response.

The company seeks to develop and sell new therapeutics using the immune system to fight cancer. ImmunoCellular is based in Los Angeles.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.